Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Small-Caps at Record Highs Ahead of Christmas

Published 12/23/2020, 06:06 AM
Updated 07/09/2023, 06:31 AM

The small-cap Russell 2000 index has hit another closing record high today — the 13th time this has occurred this year. Otherwise, it was sort of a reversal of yesterday’s close, with the S&P 500 up slightly and the Dow more solidly in the green, while the Nasdaq dipped 0.3% on the day. Energy and Financials led; Energy had been one of the underperforming industries a day ago.

A report on New Home Sales for November was released earlier today, posting a disappointing 841K from an expected the 1.0 million expected. This marks an 11% drop for the month (though still +20% year over year), and is the third straight month of lower new home sales. Short supply in housing and historically low mortgage rates have put this industry on the front burner, but homebuilders continue to struggle keeping supply in pace with demand. A month ago, 945K new homes were sold for the month.

Consumer Sentiment for December came in at 80.7, slightly lower than the 81.0 analysts were looking for, and 70 basis points below the November read of 81.4. This is only a partial look at this year’s all-important holiday shopping season. We’ll get a more well-rounded view next month and the month after, when retailers bring forth their quarterly earnings results.

Moderna (NASDAQ:MRNA) MRNA has issued a statement on its Emergency Use Application (EUA)-approved Covid-19 vaccine, and how it’s projected to perform on the variant strain of the coronavirus discovered in the south of England. The company said that because the vaccine covers the entire spike protein — the region of the mutation in the new strain — that its efficacy should not be negatively affected. This is similar to the statement released on the Pfizer PFE-BioNTech BNTX Covid-19 vaccine previously.

Tomorrow is only a half-day for the markets. Volumes tend to slow right before a big holiday, as well. This column will update ahead of the opening bell, but will not return until Monday of next week.

Questions or comments about this article and/or its author? Click here>>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Zacks Names “Single Best Pick to Double”

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer (NYSE:SAM) Company which shot up +143.0% in a little more than 9 months and Nvidia (NASDAQ:NVDA) which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Pfizer Inc. (NYSE:PFE): Free Stock Analysis Report

Moderna, Inc. (MRNA): Free Stock Analysis Report

BioNTech SE Sponsored ADR (NASDAQ:BNTX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.